{"id":818618,"date":"2026-06-10T14:23:02","date_gmt":"2026-06-10T14:23:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=818618"},"modified":"2026-06-10T14:23:02","modified_gmt":"2026-06-10T14:23:02","slug":"atopic-keratoconjunctivitis-pipeline-gains-momentum-10-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/atopic-keratoconjunctivitis-pipeline-gains-momentum-10-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight_818618.html","title":{"rendered":"Atopic Keratoconjunctivitis Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1781069723.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Atopic Keratoconjunctivitis Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1781069723.jpg\" alt=\"Atopic Keratoconjunctivitis Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, <strong>&ldquo;Atopic Keratoconjuctivitis Pipeline Insight 2026&rdquo;<\/strong> report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atopic Keratoconjuctivitis pipeline landscape. It covers the Atopic Keratoconjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Keratoconjunctivitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the latest drugs and treatment options in the Atopic Keratoconjunctivitis Pipeline @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-keratoconjuctivitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/atopic-keratoconjuctivitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Atopic Keratoconjunctivitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>In April 2026- Domp&eacute; Farmaceutici S.p.<\/em><\/strong>initiated a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. Approximately 138 participants who meet all eligibility criteria will be enrolled in the study.<\/li>\n<li>DelveInsight&rsquo;s Atopic Keratoconjunctivitis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Atopic Keratoconjunctivitis treatment.<\/li>\n<li>The leading Atopic Keratoconjunctivitis Companies such as <strong><em>Akari Therapeutics, Allakos<\/em><\/strong>, and others.<\/li>\n<li>Promising Atopic Keratoconjunctivitis Pipeline Therapies such as <strong><em>Dupilumab, Cyclosporine 0.010%<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay ahead with the most recent pipeline outlook for Atopic Keratoconjunctivitis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-keratoconjuctivitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Atopic Keratoconjunctivitis Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Keratoconjuctivitis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Atopic Keratoconjuctivitis is a noninfectious chronic inflammatory ocular-surface condition associated with other atopic conditions. AKC may occur at any time after the onset of the associated dermatitis or other atopic condition, and is not necessarily correlated with exacerbations of these conditions.<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Keratoconjunctivitis Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>rVA576: Akari Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">rVA576 is currently in Phase I\/II of clinical trial study and is being developed by Akari Therapeutics for the treatment of Atopic Keratoconjuctivitis. Thye trial got initiated in February 2019 and is expected to get completed by February 2022.<\/p>\n<p style=\"text-align: justify;\"><strong>The Atopic Keratoconjunctivitis Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Keratoconjunctivitis with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Keratoconjunctivitis Treatment.<\/li>\n<li>Atopic Keratoconjunctivitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Atopic Keratoconjunctivitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Keratoconjunctivitis market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Explore groundbreaking therapies and clinical trials in the Atopic Keratoconjunctivitis Pipeline @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-keratoconjuctivitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">New Atopic Keratoconjunctivitis Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Keratoconjunctivitis Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Akari Therapeutics, Allakos<\/em><\/strong>, and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Keratoconjuctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravitreal<\/li>\n<li>Subretinal<\/li>\n<li>Topical.<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Atopic Keratoconjunctivitis Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn about new drugs, pipeline developments with DelveInsight&#8217;s expert analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-keratoconjuctivitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Atopic Keratoconjunctivitis Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Atopic Keratoconjunctivitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Atopic Keratoconjunctivitis Companies- <strong><em>Akari Therapeutics, Allakos<\/em><\/strong>, and others.<\/li>\n<li>Atopic Keratoconjunctivitis Pipeline Therapies- <strong><em>Dupilumab, Cyclosporine 0.010% <\/em><\/strong>and others.<\/li>\n<li>Atopic Keratoconjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Atopic Keratoconjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download DelveInsight&#8217;s in-depth pipeline report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-keratoconjuctivitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Atopic Keratoconjunctivitis Companies, Key Products and Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Atopic Keratoconjuctivitis: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Atopic Keratoconjuctivitis &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>Atopic Keratoconjuctivitis Collaboration Deals<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Mid Stage Products (Phase I\/II)<\/li>\n<li>rVA576: Akari Therapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>AK002: Allakos<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Pre-clinical and Discovery Stage Products<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Atopic Keratoconjuctivitis Key Companies<\/li>\n<li>Atopic Keratoconjuctivitis Key Products<\/li>\n<li>Atopic Keratoconjuctivitis- Unmet Needs<\/li>\n<li>Atopic Keratoconjuctivitis- Market Drivers and Barriers<\/li>\n<li>Atopic Keratoconjuctivitis- Future Perspectives and Conclusion<\/li>\n<li>Atopic Keratoconjuctivitis Analyst Views<\/li>\n<li>Atopic Keratoconjuctivitis Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=atopic-keratoconjunctivitis-pipeline-gains-momentum-10-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-keratoconjuctivitis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/atopic-keratoconjuctivitis-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=atopic-keratoconjunctivitis-pipeline-gains-momentum-10-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Atopic Keratoconjuctivitis Pipeline Insight 2026&rdquo; report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atopic Keratoconjuctivitis pipeline landscape. It covers the Atopic Keratoconjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/atopic-keratoconjunctivitis-pipeline-gains-momentum-10-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight_818618.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-818618","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/818618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=818618"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/818618\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=818618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=818618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=818618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}